Komal Jhaveri: Novel Endocrine Therapies and Targeted Therapies for HR+ HER2- Breast Cancer
Komal Jhaveri, Patricia and James Cayne Chair for Junior Faculty, shared a post by Mirrors of Medicine, on LinkedIn, adding:
“Novel endocrine therapies are a great partner of choice with targeted therapies for HR positive HER2. Negative MBC.”
Quoting Mirrors of Medicine‘s post:
“Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
In a phase 3 trial involving patients with ER-positive, HER2-negative advanced Breast Cancer that had progressed after aromatase inhibitor therapy, the next-generation oral selective estrogen receptor degrader (SERD) imlunestrant demonstrated superior progression-free survival compared to standard endocrine therapy in patients with ESR1 mutations. However, this benefit was not observed in the overall study population. Notably, the combination of imlunestrant with the CDK4/6 inhibitor abemaciclib significantly improved progression-free survival compared to imlunestrant alone, regardless of ESR1 mutation status.
These findings support imlunestrant–abemaciclib as a promising therapeutic option in this setting.”
Title: Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Authors: Komal L. Jhaveri, Patrick Neven, Monica Lis Casalnuovo, Sung-Bae Kim, Eriko Tokunaga, Philippe Aftimos, Cristina Saura, Joyce O’Shaughnessy, Nadia Harbeck, Lisa A. Carey, Giuseppe Curigliano, Antonio Llombart-Cussac, Elgene Lim, María de la Luz García Tinoco, Joohyuk Sohn, André Mattar, Qingyuan Zhang, Chiun-Sheng Huang, Chih-Chiang Hung, Jorge Luis Martinez Rodriguez, Manuel Ruíz Borrego, Rikiya Nakamura, Kamnesh R. Pradhan, Christoph Cramer von Laue, Emily Barrett, Shanshan Cao, Xuejing Aimee Wang, Lillian M. Smyth, François-Clément Bidard
More posts featuring Komal Jhaveri on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023